Pharmacyclics' fifth patient enrollment in phase III Resonate study triggers ... pharmabiz.com These studies include: phase III combination study of bendamustine/rituximab plus ibrutinib versus bendamustine/rituximab plus placebo in relapsed or refractory CLL/SLL patients; phase III frontline study of single agent ibrutinib versus a comparator ... |
